24 May, 2018 |Facebook |Twitter |Email |

Targeting endosomally localized toll like receptors by Dectin 1 agonist nano vehicles

The Toll-like receptors (TLRs) are major components of the innate immune system playing an imperative role in host defense against pathogens by recognizing diverse pathogen-associated molecular patterns (PAMPs). Binding of these pathogen-associated molecular patterns triggers a complicated cascade of events leading to enhanced expression of pro-inflammatory genes.

The cytokines released as a consequence act as major players in various human ailments by providing defense on one hand and disease aggravation on the other hand.

TLRs are type I transmembrane glycoproteins and the member of interleukin-1 receptors superfamily. Ligand-dependent activation of the TLRs leads to a cascade of intracellular protein-protein interactions involving a set of adapter proteins that ultimately leads to the appropriate cellular effects. Despite the importance of TLR signaling in the innate immune system, little is known about the molecular events that trigger the signaling cascade.

The Molecular Immunology research laboratory headed by Dr. Preeti Bajpai at Integral University, focuses on elucidation of the molecular mechanisms involved in coordinating innate immunity specifically through Toll Like Receptors. Various interdisciplinary approaches including immunoinformatics, biological assays and RNA mediated silencing have been employed to reveal the structural models of unexplored TLRs and complex cascades involved in ligand interaction and thereby downstream signaling. The results achieved so far have demonstrated a novel CpG ODN, ligand of endosomally localized TLR9 as a potential adjuvant for prophylaxis of parasitic infections specifically Visceral Leishmaniasis. Additionally her group also encompasses exploration of various phyto compounds for their immunomodulatory activity routed through extracellular and endosomal Toll like receptors.

The young researchers of Molecular Immunology lab have also explored the critical role of cell cycle regulators in cancer progression by switching on and off the various pathways including MAP kinases which in turn control the downstream processing of TLRs.

Dr. Bajpai accentuates that portrayal of these immune regulators may lead towards an insight for development of novel therapeutic or prophylactic immunomodulatory agents for life threatening diseases.